Gilead Sciences Inc. (GILD) is seeking FDA approval for Tecartus in the additional indication as a treatment for adult patients with relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia, and a decision is expected on October 1, 2021.Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy, which is already approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Tecartus, which secured FDA approval for mantle cell lymphoma last July, generated total global sales of $44 million in 2020.If approved for the proposed indication, Tecartus will have to complete with Novartis’ Kymriah. GILD closed Wednesday’s trading at $70.94, up 1.39%.